Selective MAO-B inhibitor
Selegiline hydrochloride
Brand names: Eldepryl
Adult dose
Dose: 5mg PO OD morning, may increase to 10mg OD
Route: PO
Frequency: OD
Clinical pearls
- Adjunct to levodopa in Parkinson's; weak evidence as monotherapy
- Take in morning
Contraindications
- Concurrent MAOI (other)
- Pethidine
- Severe hepatic impairment
- Active duodenal ulcer
Side effects
- Insomnia
- Hypertension
- Postural hypotension
- Dyskinesia
- Hallucinations
- Impulse control disorders
Interactions
- MAOIs
- Pethidine
- SSRIs/SNRIs (serotonin syndrome)
- Sympathomimetics
- Tyramine-rich foods (high doses)
Monitoring
- BP
- Mood
- Symptoms
Reference: BNF; NICE NG71; https://bnf.nice.org.uk/drugs/selegiline-hydrochloride/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- BALL Score for Relapsed/Refractory CLL · Leukaemia
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS